Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Anteris Technologies Global Starts US PARADIGM Trial Enrolment
Anteris starts US PARADIGM enrolment; US$320m funding boosts cash to US$283m as Q1 loss widens; CMS coverage boosts TAVR prospects.
Latest Stories
Nexsen Secures First Asian Hospital Partner for Diagnostic Commercialisation
Nexsen signs binding term sheet with GHK Hospital to validate and roll out rapid point-of-care diagnostics in North Asia, starting with GBS and kidney tests.
Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study
Neurizon gains ethics approval for NUZ-001 oral liquid Phase 1 ALS study in Australia; trial slated to start Q3 2026 and finish Q4 2026.
Bioxyne Signs $50m Exclusive German Supply Deal with ADREX
Bioxyne lands $50m exclusive German supply deal with ADREXpharma, securing $25m minimum in first year, boosting Europe revenue visibility and 12-month renewal.
Biome Australia Extends Exclusive Probiotical Supply Agreement Through 2028
Biome Australia extends exclusive Probiotical supply to 2028, securing supply amid expansion; H1 FY2026 revenue $12.4m, EBITDA-positive.
EMVision Expands Pivotal FDA Trial to Include Acute Ischaemia Detection
EMVision expands FDA De Novo trial to include acute ischaemia detection for its emu device, widening indications as recruitment hits 125 and cash AUD 18.4m.
Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG
Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.
PYC Therapeutics Advances PKD Program with Phase 1b Multiple Ascending Dose Study Initiation
PYC Therapeutics kicks off Phase 1b MAD for PKD with first patient dosed in PYC-003; data due CY27, paving the way to registrational Phase 2/3 and NDA.
Nova Eye Medical Lifts FY26 Sales Guidance on Record April US Sales
Nova Eye Medical lifts FY26 US sales guidance to US$22-23m (ex-China) after record April US sales; first positive EBITDA in Q3 FY26.
Entropy Neurodynamics Reports Breakthrough Results from Phase 2a TRP-8802 Study for Treating IBS
Entropy Neurodynamics announces Phase 2a TRP-8802 IBS results: 75% responders, clear gut-brain axis effect; de-risks program ahead of TRP-8803 trials.
LTR Pharma Unveils Strong SPONTAN Data and Dual US Strategy
LTR Pharma reports SPONTAN PK: 5 mg intranasal Tmax 10 min vs 60 min oral; FDA 505(b)(2) pathway; dual US strategy; $24.1m cash, 2026 milestones
EVE Health Appoints New CEO to Lead Company Through Next Phase of Growth
EVE Health appoints COO Ben Rohr as new CEO to drive next growth phase and accelerate commercialisation; Damian Wood shifts to regulatory/medical affairs.